7-azaindole | 271-66-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 英文名称: 7-azaindole
• 英文别名: 1H-pyrrolo[2,3-b]pyridine；7-Azaindol；Haza；3H-Pyrrolo[2,3-B]pyridine
• CAS: 271-66-9
• 化学式: C₇H₆N₂
• mdl: MFCD00075874
• 分子量: 118.138
• InChiKey: MQVPEPQLLRCIIJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  25.2
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2,6-二溴吡啶 、 7-azaindole 在 potassium carbonate 、 copper(II) sulfate 作用下， 反应 4.0h， 以25%的产率得到2,6-bis(1H-pyrrolo[2,3-b]pyridin-1-yl)pyridine
  参考文献：
  名称：

  2,6-双（氮杂吲哚）吡啶：与铁（III）和铜（II）盐具有反应性。

  摘要：

  1- [6-（1H-吡咯并[2,3-b]吡啶-1-基）吡啶-2-基] -1H-吡咯并[2,3-b]吡啶-7-四氯高铁酸钾（III），（ C（19）H（14）N（5））[FeCl（4）]，（II）和[2,6-双（1H-吡咯并[2,3-b]吡啶-1-基-κN（ 7））吡啶-κN]双（硝基-κaO）铜（II），[Cu（NO（3））（2）（C（19）H（13）N（5））]，（III），通过自组装从FeCl（3）.6H（2）O或Cu（NO（3））（2）.3H（2）O和2,6-bis（1H-pyrrolo [2,3-b ]吡啶-1-基）吡啶[通常称为2,6-双（氮杂吲哚）吡啶，bap]，C（19）H（13）N（5），（I）。化合物（I）在Poverline {1}空间群中的Z'= 2结晶，两个独立的分子都采用反式-反式构型。化合物（II）是具有弱CH ... Cl相互作用的盐配合物，形成了沿a轴沿pi

  DOI：

  10.1107/s0108270107039686

文献信息

• Imidazole derivatives as PDE10A enzyme inhibitors
  申请人：Kehler Jan

  公开号：US20120129836A1

  公开（公告）日：2012-05-24

  This invention is directed to compounds, which are PDE10A enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula I. The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention also provides a method of treating a subject suffering from a drug addiction comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I.

  这项发明涉及一类PDE10A酶抑制剂化合物。该发明提供了一种包含该发明化合物的治疗有效量和药用载体的药物组合物。本发明还提供了制备式I化合物的方法。本发明还提供了一种治疗神经退行性疾病的方法，包括向患有神经退行性疾病的受试者施用式I化合物的治疗有效量。本发明还提供了一种治疗药物成瘾的方法，包括向患有药物成瘾的受试者施用式I化合物的治疗有效量。本发明还提供了一种治疗精神障碍的方法，包括向患有精神障碍的受试者施用式I化合物的治疗有效量。
• SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS
  申请人：Su Wei-Guo

  公开号：US20140121200A1

  公开（公告）日：2014-05-01

  Provided are pyridopyrazine compounds of formula (1), pharmaceutical compositions thereof and methods of use therefore, wherein R 1 , R 2 , R 3 , R 4 and m are as defined in the specification.

  提供了式（1）的吡啶吡嗪化合物，以及其药物组合物和使用方法，其中R1、R2、R3、R4和m如规范中所定义。
• INHIBITORS OF FATTY ACID AMIDE HYDROLASE
  申请人：INFINITY PHARMACEUTICALS, INC.

  公开号：US20150368278A1

  公开（公告）日：2015-12-24

  The present invention provides compounds, and pharmaceutically acceptable compositions thereof, encompassed by any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof. The present invention also provides methods for treating an FAAH mediated disease, disorder or condition by administering a therapeutically effective amount of a compound or composition comprising a compound of any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof, to a patient in need thereof. Additionally, the present invention provides methods for inhibiting FAAH by administering a therapeutically effective amount of a compound or composition comprising a compound of any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof, to a patient in need thereof.

  本发明提供了由任何公式（I）、（II）、（III）、（IV）、（V）或（VI）中的任何化合物及其药学上可接受的组合物所包含的范围，或其亚属所包含的范围。本发明还提供了通过向需要的患者投与任何公式（I）、（II）、（III）、（IV）、（V）或（VI）中的任何化合物或其组合物的治疗有效量来治疗FAAH介导的疾病、紊乱或症状的方法。此外，本发明提供了通过向需要的患者投与任何公式（I）、（II）、（III）、（IV）、（V）或（VI）中的任何化合物或其组合物的治疗有效量来抑制FAAH的方法。
• HALOGENATED COMPOUNDS FOR PHOTODYNAMIC THERAPY
  申请人：Jones Gary W.

  公开号：US20130231604A1

  公开（公告）日：2013-09-05

  Halo-organic heterocyclic compounds are described, in which at least two halogen atoms are bound to a nitrogen-containing heterocyclic terminal moiety of the compound, with at least one of such halogen atoms being iodine or bromine. Also described are polymethine dyes based on these heterocyclic compounds, and dendrimeric compounds and conjugates of such polymethine dyes. The polymethine dyes are characterized by enhanced properties, e.g., brightness, photostability, sensitivity and/or selective affinity that make them useful to target cancer cells, pathogenic microorganisms, and/or other biological materials, in applications such as photodynamic therapy, photodynamic antimicrobial chemotherapy (PACT), cancer treatment, selective removal or attachment of biological materials, antimicrobial coating materials, and other diagnostic, theranostic, spectrum shifting, deposition/growth, and analytic applications.

  描述了卤素有机杂环化合物，其中至少有两个卤素原子与化合物的含氮杂环末端基团结合，其中至少一个卤素原子为碘或溴。还描述了基于这些杂环化合物的聚甲烯染料，以及这些聚甲烯染料的树枝状化合物和共轭物。这些聚甲烯染料具有增强的性能，例如亮度、光稳定性、灵敏度和/或选择性亲和力，使它们在靶向癌细胞、病原微生物和/或其他生物材料的应用中具有用途，例如光动力疗法、光动力抗微生物化疗（PACT）、癌症治疗、选择性去除或附着生物材料、抗微生物涂层材料以及其他诊断、治疗学、光谱转移、沉积/生长和分析应用。
• POLYMERIZABLE COMPOUND, POLYMERIZABLE COMPOSITION, POLYMER, OPTICALLY ANISOTROPIC BODY, AND METHOD FOR PRODUCING POLYMERIZABLE COMPOUND
  申请人：ZEON CORPORATION

  公开号：US20150175564A1

  公开（公告）日：2015-06-25

  A polymerizable compound has a practical low melting point, excellent solubility in a general-purpose solvent, and can produce an optical film at low cost, exhibits low reflected luminance, and achieves uniform conversion of polarized light over a wide wavelength band, an optically anisotropic article. A carbonyl compound is useful as a raw material for producing the polymerizable compound. (In the formula (I), Y 1 to Y 8 represent —C(═O)—O—, G 1 and G 2 represent a C 1-20 divalent linear aliphatic group, Z 1 and Z 2 represent a C 2-10 alkenyl group that is unsubstituted, or substituted with a halogen atom, A x represents a C 2-30 organic group with at least one aromatic ring, A y represents a hydrogen atom or C 1-20 alkyl group, A 1 represents a trivalent aromatic group, A 2 and A 3 represent a C 3-30 divalent alicyclic hydrocarbon group, A 4 and A 5 represent a C 6-30 divalent aromatic group or the like, and Q 1 represents a hydrogen atom.)

  一种可聚合的化合物具有实用的低熔点、在通用溶剂中良好的溶解性，并且可以以低成本制备光学薄膜，表现出较低的反射亮度，并且在宽波长范围内实现偏振光的均匀转换，是一种光学各向异性材料。一种羰基化合物可作为制备可聚合化合物的原料。（在式（I）中，Y1至Y8代表—C(═O)—O—，G1和G2代表C1-20二价线性脂肪族基团，Z1和Z2代表未取代或取代有卤素原子的C2-10烯基基团，Ax代表至少具有一个芳香环的C2-30有机基团，Ay代表氢原子或C1-20烷基基团，A1代表三价芳香族基团，A2和A3代表C3-30二价脂环碳氢基团，A4和A5代表C6-30二价芳香族基团或类似物，Q1代表氢原子。）